Welcome to the homepage for final product lot release testing. All biologicals being released into global pharmaceutical markets require GMP testing of final product packages to demonstrate compliance with regulatory guidelines.
At BioReliance, we offer a wide range of assays and services aimed at ensuring the quality and purity of final biologicals products for the pharmaceutical and biotech industries.
Recommended services for final product lot release testing:
Custom final product lot release testing services also are available.
Contact BioReliance and our research team will be happy to assist you in planning your biological production methodology.
More about Final Product Lot Release Testing
Every lot of product produced, both for preclinical and clinical studies, requires a series of tests to ensure active ingredients are free of contaminants according to 21 CFR 211.165 and 21 CFR 610. This testing should be performed separate from final container testing.
Final product should be below acceptable levels for endotoxin and pyrogen levels, free of residual solvents and DNA, and be tested by lot prior to release.
Let the CRO experts at BioReliance, help your team ensure the safety with a carefully planned and executed final product lot release testing program.
Apps, Tools, Newsletters & More...
Find the latest scientific resources from Sigma-Aldrich.
Copyright © 2016 Sigma-Aldrich Co. LLC. All Rights Reserved. Reproduction of any materials from the site is strictly forbidden without permission. Sigma-Aldrich brand products are sold exclusively through Sigma-Aldrich Co. LLC. Sigma-Aldrich Corp. is a subsidiary of Merck KGaA, Darmstadt, Germany Terms | Privacy | Site Map